Company intelligence / Profile preview
ActualEyes
Kyoto, Kyoto-fu, Japanactualeyes.co.jp ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate AE001 (sirolimus eye drops) is in Phase 2 (POC) clinical trials for Fuchs endothelial corneal dystrophy in the US, in collaboration with Santen. AE101 (cell therapy) is licensed to Arctic Vision in Greater China and South Korea, and is preparing for clinical trials in Japan.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculeCell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Santen Pharmaceuticals (co-development and clinical trials for AE001)Arctic Vision (Greater China, South Korea licensee for AE101)D. Western Therapeutics Institute (co-development in Japan for AE101)Japan Tissue Engineering (manufacturing AE101 for Japan)
Beyond the preview
Go deeper on ActualEyes.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ActualEyes.